

## TRANSDERMAL DRUG DELIVERY SYSTEM: AN OVERVIEW

**J. Ashok kumar<sup>1\*</sup>, Nikhila pullakandam<sup>1</sup>, S.Lakshmana prabu<sup>2</sup>, V.Gopal.<sup>3</sup>**

- 1. Faculty of Pharmacy, PRIST University, Thanjavur, Tamilnadu-614904.
- 2. Dept. of Pharm Technology, Anna University Tiruchirappalli.- 620024
- 3. Mother Theresa Institute of Health Sciences, Puducherry- 605006

**\*Email:** [akpharm@gmail.com](mailto:akpharm@gmail.com)

### **ABSTRACT**

Today about 74% of drugs are taken orally and are found not to be as effective as desired. To improve such characters transdermal drug delivery system was emerged. Drug delivery through the skin to achieve a systemic effect of a drug is commonly known as transdermal drug delivery and differs from traditional topical drug delivery. Transdermal drug delivery systems (TDDS) are dosage forms involves drug transport to viable epidermal and or dermal tissues of the skin for local therapeutic effect while a very major fraction of drug is transported into the systemic blood circulation. The adhesive of the transdermal drug delivery system is critical to the safety, efficacy and quality of the product. Topical administration of therapeutic agents offers many advantages over conventional oral and invasive methods of drug delivery. Several important advantages of transdermal drug delivery are limitation of hepatic first pass metabolism, enhancement of therapeutic efficiency and maintenance of steady plasma level of the drug. This article provides an overview of types of Transdermal patches, methods of preparation and its physicochemical methods of evaluation.

**Keywords:** TDDS, Topical drug delivery, Systemic blood circulation.

### **INTRODUCTION**

Transdermal drug delivery systems (TDDS), also known as “patches,” are dosage forms designed to deliver a therapeutically effective amount of drug across a patient’s skin. In order to deliver therapeutic agents through the human skin for systemic effects, the comprehensive morphological, biophysical and physicochemical properties of the skin are to be considered. Transdermal delivery provides a leading edge over injectables and oral routes by increasing patient compliance and avoiding first pass metabolism respectively<sup>1</sup>. Transdermal delivery not only provides controlled, constant administration of the drug, but also allows continuous input of drugs with short biological half-lives and eliminates pulsed entry into systemic circulation, which often causes undesirable side effects. Thus various forms of Novel drug delivery system such as Transdermal drug delivery systems, Controlled release systems, Transmucosal delivery systems etc. emerged. Several important advantages of transdermal drug delivery are limitation of hepatic first pass metabolism, enhancement of therapeutic efficiency and maintenance of steady plasma level of the drug. The first Transdermal system, Transderm-SCOP was approved by FDA in 1979 for the prevention of nausea and vomiting associated with travel, particularly by sea. The evidence of percutaneous drug absorption may be found through measurable blood levels of the drug, detectable excretion of the drug and its metabolites in the urine and through the clinical response of the patient to the administered drug therapy.<sup>2</sup>

The common ingredients which are used for the preparation of TDDS are as follows.<sup>3</sup>

- ❖ Drug: Drug is in direct contact with release liner. Ex: Nicotine, Methotrexate and Estrogen.

- ❖ Liners: Protects the patch during storage. Ex: polyester film.
- ❖ Adhesive: Serves to adhere the patch to the skin for systemic delivery of drug. Ex: Acrylates, Polyisobutylene, Silicones.
- ❖ Permeation enhancers: Controls the Release of the drug. Ex: Terpenes, Terpenoids, Pyrrolidones. Solvents like alcohol, Ethanol, Methanol. Surfactants like Sodium Lauryl sulfate, Pluronic F127, Pluronic F68.
- ❖ Backing layer: Protect patch from outer environment. Ex: Cellulose derivatives, poly vinyl alcohol, Polypropylene Silicon rubber.

### **TYPES OF TRANSDERMAL PATCHES:**<sup>4-8</sup>

#### **a) Single layer drug in adhesive:**

In this type the adhesive layer contains the drug. The adhesive layer not only serves to adhere the various layers together and also responsible for the releasing the drug to the skin. The adhesive layer is surrounded by a temporary liner and a backing.

#### **b) Multi -layer drug in adhesive:**

This type is also similar to the single layer but it contains a immediate drug release layer and other layer will be a controlled release along with the adhesive layer. The adhesive layer is responsible for the releasing of the drug. This patch also has a temporary liner-layer and a permanent backing.

#### **c) Vapour patch:**

In this type of patch the role of adhesive layer not only serves to adhere the various layers together but also serves

as release vapour. The vapour patches are new to the market, commonly used for releasing of essential oils in decongestion. Various other types of vapor patches are also available in the market which are used to improve the quality of sleep and reduces the cigarette smoking conditions.

#### **d) Reservoir system:**

In this system the drug reservoir is embedded between an impervious backing layer and a rate controlling membrane. The drug releases only through the rate-controlling membrane, which can be micro porous or non porous. In the drug reservoir compartment, the drug can be in the form of a solution, suspension, gel or dispersed in a solid polymer matrix. Hypoallergenic adhesive polymer can be applied as outer surface polymeric membrane which is compatible with drug.

#### **e) Matrix system:**

##### **i. Drug-in-adhesive system:**

In this type the drug reservoir is formed by dispersing the drug in an adhesive polymer and then spreading the medicated adhesive polymer by solvent casting or melting (in the case of hot-melt adhesives) on an impervious backing layer. On top of the reservoir, unmediated adhesive polymer layers are applied for protection purpose.

##### **ii. Matrix-dispersion system:**

In this type the drug is dispersed homogenously in a hydrophilic or lipophilic polymer matrix. This drug containing polymer disk is fixed on to an occlusive base plate in a compartment fabricated from a drug impermeable backing layer. Instead of applying the adhesive on the face of the drug reservoir, it is spread along with the circumference to form a strip of adhesive rim.

##### **f) Microreservoir system:**

In this type the drug delivery system is a combination of reservoir and matrix-dispersion system. The drug reservoir is formed by first suspending the drug in an aqueous solution of water soluble polymer and then dispersing the solution homogeneously in a lipophilic polymer to form thousands of unreachable, microscopic spheres of drug reservoirs. This thermodynamically unstable dispersion is stabilized quickly by immediately cross-linking the polymer in situ by using cross linking agents.

### **VARIOUS METHODS FOR PREPARATION TDDS:**

#### **a. Asymmetric TPX membrane method:<sup>9</sup>**

A prototype patch can be fabricated for this a heat sealable polyester film (type 1009, 3m) with a concave of 1cm diameter will be used as the backing membrane. Drug sample is dispensed into the concave membrane, covered by a TPX {poly(4-methyl-1-pentene)} asymmetric membrane, and sealed by an adhesive.

**[(Asymmetric TPX membrane preparation):** These are fabricated by using the dry/wet inversion process. TPX is dissolved in a mixture of solvent (cyclohexane) and nonsolvent additives at 60°C to form a polymer solution.

The polymer solution is kept at 40°C for 24 hrs and cast on a glass plate to a pre-determined thickness with a gardner knife. After that the casting film is evaporated at 50°C for 30 sec, then the glass plate is to be immersed immediately in coagulation bath [maintained the temperature at 25°C]. After 10 minutes of immersion, the membrane can be removed, air dry in a circulation oven at 50°C for 12 hrs].

#### **b. Circular teflon mould method:<sup>10</sup>**

Solutions containing polymers in various ratios are used in an organic solvent. Calculated amount of drug is dissolved in half the quantity of same organic solvent. Enhancers in different concentrations are dissolved in the other half of the organic solvent and then added. Di-N-butylphthalate is added as a plasticizer into drug polymer solution. The total contents are to be stirred for 12 hrs and then poured into a circular teflon mould. The moulds are to be placed on a leveled surface and covered with inverted funnel to control solvent vaporization in a laminar flow hood model with an air speed of 0.5 m/s. The solvent is allowed to evaporate for 24 hrs. The dried films are to be stored for another 24 hrs at 25±0.5°C in a desiccators containing silica gel before evaluation to eliminate aging effects. The type films are to be evaluated within one week of their preparation.

#### **c. Mercury substrate method:<sup>11</sup>**

In this method drug is dissolved in polymer solution along with plasticizer. The above solution is to be stirred for 10-15 minutes to produce a homogenous dispersion and poured in to a leveled mercury surface, covered with inverted funnel to control solvent evaporation.

#### **d. By using “IPM membranes” method:<sup>12</sup>**

In this method drug is dispersed in a mixture of water and propylene glycol containing carbomer 940 polymer and stirred for 12 hrs in magnetic stirrer. The dispersion is to be neutralized and made viscous by the addition of triethanolamine. Buffer pH 7.4 can be used in order to obtain solution gel, if the drug solubility in aqueous solution is very poor. The formed gel will be incorporated in the IPM membrane.

#### **e. By using “EVAC membranes” method:<sup>13</sup>**

In order to prepare the target transdermal therapeutic system, 1% carbopol reservoir gel, polyethylene (PE), ethylene vinyl acetate copolymer (EVAC) membranes can be used as rate control membranes.

If the drug is not soluble in water, propylene glycol is used for the preparation of gel. Drug is dissolved in propylene glycol, carbopol resin will be added to the above solution and neutralized by using 5% w/w sodium hydroxide solution. The drug (in gel form) is placed on a sheet of backing layer covering the specified area. A rate controlling membrane will be placed over the gel and the edges will be sealed by heat to obtain a leak proof device.

#### **f. Aluminium backed adhesive film method:<sup>14</sup>**

Transdermal drug delivery system may produce unstable matrices if the loading dose is greater than 10 mg. Aluminium backed adhesive film method is a suitable one.

For preparation of same, chloroform is choice of solvent, because most of the drugs as well as adhesive are soluble in chloroform. The drug is dissolved in chloroform and adhesive material will be added to the drug solution and dissolved. A custommade aluminium former is lined with aluminium foil and the ends blanked off with tightly fitting cork blocks.

#### **g. Preparation of TDDS by using Proliposomes:<sup>15,16</sup>**

The proliposomes are prepared by carrier method using film deposition technique. From the earlier reference drug and lecithin in the ratio of 0.1:2.0 can be used as an optimized one. The proliposomes are prepared by taking 5mg of mannitol powder in a 100 ml round bottom flask which is kept at 60-70°C temperature and the flask is rotated at 80-90 rpm and dried the mannitol at vacuum for 30 minutes. After drying, the temperature of the water bath is adjusted to 20-30°C. Drug and lecithin are dissolved in a suitable organic solvent mixture, a 0.5ml aliquot of the organic solution is introduced into the round bottomed flask at 37°C, after complete drying second aliquots (0.5ml) of the solution is to be added. After the last loading, the flask containing proliposomes are connected in a lyophilizer and subsequently drug loaded mannitol powders (proliposomes) are placed in a desiccator over night and then sieved through 100 mesh. The collected powder is transferred into a glass bottle and stored at the freeze temperature until characterization.

#### **h. By using free film method:<sup>17</sup>**

Free film of cellulose acetate is prepared by casting on mercury surface. A polymer solution 2% w/w is to be prepared by using chloroform. Plasticizers are to be incorporated at a concentration of 40% w/w of polymer weight. Five ml of polymer solution was poured in a glass ring which is placed over the mercury surface in a glass petri dish. The rate of evaporation of the solvent is controlled by placing an inverted funnel over the petri dish. The film formation is noted by observing the mercury surface after complete evaporation of the solvent. The dry film will be separated out and stored between the sheets of wax paper in a desiccator until use. Free films of different thickness can be prepared by changing the volume of the polymer solution.

### **EVALUATION PARAMETERS:**

#### **1. Interaction studies:<sup>18,19</sup>**

Excipients are integral components of almost all pharmaceutical dosage forms. The stability of a formulation amongst other factors depends on the compatibility of the drug with the excipients. The drug and the excipients must be compatible with one another to produce a product that is stable, thus it is mandatory to detect any possible physical or chemical interaction as it can affect the bioavailability and stability of the drug. If the excipients are new and have not been used in formulations containing the active substance, the compatibility studies play an important role in formulation development. Interaction studies are commonly carried out in Thermal analysis, FT-IR, UV and chromatographic techniques by comparing their physicochemical characters

such as assay, melting endotherms, characteristic wave numbers, absorption maxima etc.,

#### **2. Thickness of the patch:<sup>20</sup>**

The thickness of the drug loaded patch is measured in different points by using a digital micrometer and determines the average thickness and standard deviation for the same to ensure the thickness of the prepared patch.

#### **3. Weight uniformity:<sup>20</sup>**

The prepared patches are to be dried at 60°C for 4hrs before testing. A specified area of patch is to be cut in different parts of the patch and weigh in digital balance. The average weight and standard deviation values are to be calculated from the individual weights.

#### **4. Folding endurance:<sup>20</sup>**

A strip of specific area is to be cut evenly and repeatedly folded at the same place till it broke. The number of times the film could be folded at the same place without breaking gave the value of the folding endurance.

#### **5. Percentage Moisture content:<sup>20</sup>**

The prepared films are to be weighed individually and to be kept in a desiccator containing fused calcium chloride at room temperature for 24 hrs. After 24 hrs the films are to be reweighed and determine the percentage moisture content from the below mentioned formula.

Percentage moisture content = [Initial weight - Final weight / Final weight] × 100.

#### **6. Percentage Moisture uptake:<sup>20</sup>**

The weighed films are to be kept in a desiccator at room temperature for 24 hrs containing saturated solution of potassium chloride in order to maintain 84% RH. After 24 hrs the films are to be reweighed and determine the percentage moisture uptake from the below mentioned formula.

Percentage moisture uptake = [Final weight - Initial weight / initial weight] × 100.

#### **7. Water vapour permeability (WVP) evaluation:<sup>21</sup>**

Water vapour permeability can be determined with foam dressing method the air forced oven is replaced by a natural air circulation oven. The WVP can be determined by the following formula

$$\text{WVP} = \frac{W}{A}$$

Where, WVP is expressed in gm/m<sup>2</sup> per 24hrs,

W is the amount of vapour permeated through the patch expressed in gm/24hrs and A is the surface area of the exposure samples expressed in m<sup>2</sup>.

#### **8. Drug content:<sup>21</sup>**

A specified area of patch is to be dissolved in a suitable solvent in specific volume. Then the solution is to be filtered through a filter medium and analyse the drug contain with the suitable method (UV or HPLC technique). Each value represents average of three different samples.

### **9. Uniformity of dosage unit test:<sup>22</sup>**

An accurately weighed portion of the patch is to be cut into small pieces and transferred to a specific volume volumetric flask, dissolved in a suitable solvent and sonicate for complete extraction of drug from the patch and made up to the mark with same. The resulting solution was allowed to settle for about an hour, and the supernatant was suitably diluted to give the desired concentration with suitable solvent. The solution was filtered using 0.2µm membrane filter and analysed by suitable analytical technique (UV or HPLC) and the drug content per piece will be calculated.

### **10. Polariscopic examination:<sup>22</sup>**

This test is to be performed to examine the drug crystals from patch by polariscope. A specific surface area of the piece is to be kept on the object slide and observe for the drugs crystals to distinguish whether the drug is present as crystalline form or amorphous form in the patch.

### **11. Shear Adhesion test:<sup>22</sup>**

This test is to be performed for the measurement of the cohesive strength of an adhesive polymer. It can be influenced by the molecular weight, the degree of crosslinking and the composition of polymer, type and the amount of tackifier added. An adhesive coated tape is applied onto a stainless steel plate; a specified weight is hung from the tape, to affect it pulling in a direction parallel to the plate. Shear adhesion strength is determined by measuring the time it takes to pull the tape off the plate. The longer the time taken for removal, greater is the shear strength.

### **12. Peel Adhesion test:<sup>22</sup>**

In this test, the force required to remove an adhesive coating from a test substrate is referred to as peel adhesion. Molecular weight of adhesive polymer, the type and amount of additives are the variables that determined the peel adhesion properties. A single tape is applied to a stainless steel plate or a backing membrane of choice and then tape is pulled from the substrate at a 180° angle, and the force required for tape removed is measured.

### **13. Thumb tack test:<sup>22</sup>**

It is a qualitative test applied for tack property determination of adhesive. The thumb is simply pressed on the adhesive and the relative tack property is detected.

### **14. Flatness test:<sup>23</sup>**

Three longitudinal strips are to be cut from each film at different portion like one from the center, other one from the left side, and another one from the right side. The length of each strip was measured and the variation in length because of non-uniformity in flatness was measured by determining percent constriction, with 0% constriction equivalent to 100% flatness.

### **15. Percentage Elongation break test:<sup>24</sup>**

The percentage elongation break is to be determined by noting the length just before the break point, the percentage elongation can be determined from the below mentioned formula.

$$\text{Elongation percentage} = \frac{L_1 - L_2}{L_2} \times 100$$

Where, L<sub>1</sub> is the final length of each strip and L<sub>2</sub> is the initial length of each strip.

### **16. Rolling ball tack test:<sup>25</sup>**

This test measures the softness of a polymer that relates to tack. In this test, stainless steel ball of 7/16 inches in diameter is released on an inclined track so that it rolls down and comes into contact with horizontal, upward facing adhesive. The distance the ball travels along the adhesive provides the measurement of tack, which is expressed in inch.

### **17. Quick Stick (peel-tack) test:<sup>25</sup>**

In this test, the tape is pulled away from the substrate at 90°C at a speed of 12 inches/min. The peel force required to break the bond between adhesive and substrate is measured and recorded as tack value, which is expressed in ounces or grams per inch width.

### **18. Probe Tack test:<sup>25</sup>**

In this test, the tip of a clean probe with a defined surface roughness is brought into contact with adhesive, and when a bond is formed between probe and adhesive. The subsequent removal of the probe mechanically breaks it. The force required to pull the probe away from the adhesive at fixed rate is recorded as tack and it is expressed in grams.

### **19. *In vitro* drug release studies:<sup>18</sup>**

The paddle over disc method (USP apparatus V) can be employed for assessment of the release of the drug from the prepared patches. Dry films of known thickness is to be cut into definite shape, weighed, and fixed over a glass plate with an adhesive. The glass plate was then placed in a 500-mL of the dissolution medium or phosphate buffer (pH 7.4), and the apparatus was equilibrated to 32± 0.5°C. The paddle was then set at a distance of 2.5 cm from the glass plate and operated at a speed of 50 rpm. Samples (5-mL aliquots) can be withdrawn at appropriate time intervals up to 24 h and analyzed by UV spectrophotometer or HPLC. The experiment is to be performed in triplicate and the mean value can be calculated.

### **20. *In vitro* skin permeation studies:<sup>18</sup>**

An in vitro permeation study can be carried out by using diffusion cell. Full thickness abdominal skin of male Wistar rats weighing 200 to 250g. Hair from the abdominal region is to be removed carefully by using a electric clipper; the dermal side of the skin was thoroughly cleaned with distilled water to remove any adhering tissues or blood vessels, equilibrated for an hour in dissolution medium or phosphate buffer pH 7.4 before starting the experiment and was placed on a magnetic stirrer with a small magnetic needle for uniform distribution of the diffusant. The temperature of the cell was maintained at 32 ± 0.5°C using a thermostatically controlled heater. The isolated rat skin piece is to be mounted between the compartments of the diffusion cell, with the epidermis facing upward into the donor

compartment. Sample volume of definite volume is to be removed from the receptor compartment at regular intervals, and an equal volume of fresh medium is to be replaced. Samples are to be filtered through filtering medium and can be analyzed spectrophotometrically or HPLC. Flux can be determined directly as the slope of the curve between the steady-state values of the amount of drug permeated ( $\text{mg cm}^{-2}$ ) vs. time in hours and permeability coefficients were deduced by dividing the flux by the initial drug load ( $\text{mg cm}^{-2}$ ).

## 21. Skin Irritation study:<sup>22</sup>

Skin irritation and sensitization testing can be performed on healthy rabbits (average weight 1.2 to 1.5 kg). The dorsal surface ( $50\text{cm}^2$ ) of the rabbit is to be cleaned and remove the hair from the clean dorsal surface by shaving and clean the surface by using rectified spirit and the representative formulations can be applied over the skin. The patch is to be removed after 24 hr and the skin is to be observed and classified into 5 grades on the basis of the severity of skin injury.

## 22. Stability studies:<sup>18</sup>

Stability studies are to be conducted according to the ICH guidelines by storing the TDDS samples at  $40 \pm 0.5^\circ\text{C}$  and  $75 \pm 5\%$  RH for 6 months. The samples were withdrawn at 0, 30, 60, 90 and 180 days and analyze suitably for the drug content.

## CONCLUSION

This article provide an valuable information regarding the transdermal drug delivery systems and its evaluation process details as a ready reference for the research scientist who are involved in TDDS. The foregoing shows that TDDS have great potentials, being able to use for both hydrophobic and hydrophilic active substance into promising deliverable drugs. To optimize this drug delivery system, greater understanding of the different mechanisms of biological interactions, and polymer are required. TDDS a realistic practical application as the next generation of drug delivery system

## REFERENCES

1. Jain NK. Advances in controlled and novel drug delivery, 1<sup>st</sup> Ed., CBS Publishers and distributors, New Delhi, 2001 pp.108-110.
2. Loyd V. Allen Jr, Nicholas G. Popovich, Howard C. Ansel. Pharmaceutical dosage forms and drug delivery systems, 8<sup>th</sup> Edition., Wolter Kluwer Publishers, New Delhi, 2005 pp. 298-299.
3. Chein Y.W. Transdermal drug delivery and delivery system. In, Novel drug delivery system, Vol. 50, Marcel Dekker, Inc., New York, 1992 pp.301-381.
4. Williams A.C and Barry B. W., "Penetration Enhancers," Adv. Drug Del. Rev. 2004;56: 603-618.
5. Pellet M, Raghavan S.L, Hadgraft J and Davis A.F. "The application of supersaturated systems to percutaneous drug delivery" In: Guy R.H and Hadgraft J. Transdermal drug delivery, Marcel Dekker, Inc., New York 2003pp. 305-326.
6. Brown M.B and Jones S.A. Hyaluronic acid: a unique topical vehicle for localized drug delivery of drugs to the skin. JEDV 2000;19:308-318.
7. Tsai J.C, Guy R.H, Thornfeldt C.R, Gao W.N, Feingold K.R and Elias P.M. "Metabolic Approaches to Enhance Transdermal drug delivery". Jour. pharm. Sci., 1998; 85:643-648.
8. Berner B and John V.A. Pharmacokinetic characterization of Transdermal delivery systems. Jour. Clinical pharmacokinetics 1994; 26 (2): 121-34.
9. Baker W and Heller J. "Material Selection for Transdermal Delivery Systems", In Transdermal Drug Delivery: Developmental Issues and Research Initiatives, J. Hadgraft and R.H. Guys, Eds. Marcel Dekker, Inc., New York 1989 pp. 293-311.
10. Wiechers J. Use of chemical penetration enhancers in Transdermal drug delivery-possibilities and difficulties. Acta pharm. 1992 : 4: 123.
11. Yamamoto T, Katakabe k, Akiyoshi K, Kan K and Asano T. Topical application of glibenclamide lowers blood glucose levels in rats. Diabetes res. Clin. Pract. 1990; 8: 19-22.
12. Al-Khamis K, Davis S.S and Hadgraft J. Microviscosity and drug release from topical gel formulations. Pharm. Res. 1986; 3: 214-217.
13. Anon. Transdermal delivery systems-general drug release standards. Pharmacopeial Forum, 1980; 14: 3860-3865.
14. Mayorga P, Puisieux F and Couarraz G. Formulation study of a Transdermal delivery system of primaquine. Int. J. pharm. 1996; 132: 71-79.
15. Deo M.R, Sant V.P, Parekh S.R, Khopade A.J and Banakar U.V. Proliposome-based Transdermal delivery of levonorgestrel. Jour. Biomat. Appl. 1997; 12: 77-88.
16. Yan-yu X, Yun-me S, Zhi-Peng C and Qi-nerg P. Preparation of silymarin proliposomes; A new way to increase oral bioavailability of silymarin in beagle dogs. Int. pharm. 2006; 319: 162-168.
17. Crawford R.R and Esmerian O.K. Effect of plasticizers on some physical properties of cellulose acetate phthalate films. J. Pharm. Sci. 1997;60: 312-314.
18. Singh J, Tripathi K.T and Sakia T.R. Effect of penetration enhancers on the *invitro* transport of ephedrine through rat skin and human epidermis from matrix based Transdermal formulations. Drug Dev. Ind. Pharm. 1993; 19: 1623-1628.
19. Wade A, Weller P.J. Handbook of pharmaceutical Excipients. Washington, DC: American Pharmaceutical Publishing Association; 1994: 362-366.

20. Rhaghuram reddy k, Muttalik S and Reddy S. Once – daily sustained- release matrix tablets of nicorandil: formulation and *invitro* evaluation. AAPS Pharm.Sci.Tech. 2003;4:4.
21. Shaila L, Pandey S and Udupa N. Design and evaluation of matrix type membrane controlled Transdermal drug delivery system of nicotine suitable for use in smoking cessation. Indian Journ. Pharm. Sci. 2006;68: 179-184
22. Aarti N, Louk A.R.M.P, Russel.O.P and Richard H.G. Mechanism of oleic acid induced skin permeation enhancement *in vivo* in humans. Jour. control. Release 1995; 37: 299-306.
23. Wade A and Weller P.J. Handbook of pharmaceutical Excipients. Washington, DC: American Pharmaceutical Publishing Association 1994; 362-366.
24. Lec S.T, Yac S.H, Kim S.W and Berner B. One way membrane for Transdermal drug delivery systems / system optimization. Int. J Pharm. 1991; 77: 231 - 237.
25. Vyas S.P and Khar R.K. Targetted and controlled Drug Delivery Novel carrier system<sup>1st</sup> Ed., CBS Publishers and distributors, New Delhi, 2002; 411-447.

\*\*\*\*\*